Phase 3 results posted: This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Hoffmann-La Roche
Why now
Thesis: Roche MS long-term data posted, outcome unclear
Catalyst to watch: Label updates or competitor readouts
Main risk: Safety signals over long-term use
Why it matters
Ocrelizumab extension study results in MS support Roche's franchise durability, but outcomes are not summarized.
Details
Sponsor: Hoffmann-La Roche; Status: Completed; Conditions: Multiple Sclerosis; Interventions: Ocrelizumab; Enrollment: 1055 (actual); First posted: 2018-07-26; Results posted: 2026-09-25; NCT: NCT03599245
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-25 12:00 UTC